BioMed Research International / 2014 / Article / Tab 1 / Research Article
Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry Table 1 Time dependent rates of HER2 analyses.
Year of diagnosis Number of patients (
) HER2 status unknown (
, %) HER2 status analyzed (
, %) HER2 negative (
, %) HER2 positive (
, %) 2000 430 360 (83.7%) 70 (16.3%) 49 (70.0%) 21 (30.0%) 2001 456 137 (30.0%) 319 (70.0%) 236 (74.0%) 83 (26.0%) 2002 455 72 (15.8%) 383 (84.2%) 304 (79.4%) 79 (20.6%) 2003 518 68 (13.1%) 450 (86.9%) 351 (78.0%) 99 (22.0%) 2004 568 52 (9.2%) 516 (90.8%) 421 (81.6%) 95 (18.4%) 2005 569 34 (6.0%) 535 (94.0%) 438 (81.9%) 97 (18.1%) 2006 527 8 (1.5%) 519 (98.5%) 409 (78.8%) 110 (21.2%) 2007 570 34 (6.0%) 536 (94.0%) 439 (81.9%) 97 (18.1%) 2008 560 47 (8.4%) 513 (91.6%) 423 (82.5%) 90 (17.5%) 2009 666 5 (0.8%) 661 (99.2%) 544 (82.3%) 117 (17.7%) 2010 589 6 (1.0%) 583 (99.0%) 469 (80.4%) 114 (19.6%) 2011 543 2 (0.4%) 541 (99.6%) 476 (88.0%) 65 (12.0%) 2012 540 2 (0.4%) 538 (99.6%) 471 (87.5%) 67 (12.5%) Total 6991 827 (11.8%) 6164 (88.2%) 5030 (81.6%) 1134 (18.4%)